Prof Foà (Sapienza University of Rome, Rome, Italy) and Prof Hillmen (St James’ University Hospital, Leeds, UK) discuss new emerging therapies for the treatment of chronic lymphocytic leukaemia (CLL) for ecancertv at a CLL treatment practice meeting in Madrid.

Together, they look at these new therapies and the differences between them, discussing the practical considerations when administering these new agents. They also consider the different side effect profile of each agent and the ways in which these can be best managed.

This programme has been supported by an unrestricted educational grant from Janssen Pharmaceutica (A Johnson & Johnson Company).